Коморбидность заболеваний печени и билиарного тракта
Заболевания желчевыводящих путей являются одними из самых распространенных (10–20% среди взрослой популяции в развитых странах) и дорогостоящих заболеваний органов пищеварения в мире. Помимо патологии желчевыводящих путей, хронические заболевания печени являются важной глобальной проблемой общественного здравоохранения. Частота выявления камней в желчном пузыре при хронических болезнях печени, как правило, высокая. Распространенность заболеваний желчевыводящих путей может быть связана с возрастом, полом, этиологией и тяжестью заболевания у пациентов с хроническими болезнями печени. Авторы настоящей статьи связали эпидемиологию, механизмы и стратегии ранней диагностики и лечения билиарной патологии у пациентов с хроническими заболеваниями печени. Остаются вопросы, на каком этапе нужно оценивать состояние билиарного тракта и какую коррекцию проводить, чтобы избежать грозных осложнений. Гимекромон сегодня позиционируется только как селективный холеспазмолитик c холеретическим действием при дисфункции билиарного тракта, в т.ч. при спазме сфинктера Одди, но без холекинетической активности, что делает применение гимекромона безопасным при желчнокаменной болезни. Но среди его плейотропных эффектов описан и антифибротический эффект при заболеваниях печени. Авторы представляют фармакохимический сравнительный анализ оригинального Гимекромона и его дженериков.Плотникова Е.Ю., Вологжанина Л.Г., Азанов А.З., Сухих А.С.
Ключевые слова
хронические заболевания печени
фиброз печени
цирроз печени
патология билиарного тракта
желчнокаменная болезнь
Гимекромон
Список литературы
1. Shehadi W.H. The biliary system through the ages. Int Surg. 1979 Nov-Dec;64(6):63–78.
2. Gibney E..J. Asymptomatic gallstones. Br J Surg. 1990 Apr;77(4):368–72. doi: 10.1002/bjs.1800770405.
3. Yang T., Zhong J., Zhang R., et al. Different types and numbers metabolic abnormalities and risk of gallbladder stone disease in adults. Front Nutr. 2024 Sep 9;11:1443575. doi: 10.3389/fnut.2024.1443575.
4. Acalovschi M. Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol. 2014 Jun 21;20(23):7277–85. doi: 10.3748/wjg.v20.i23.7277.
5. Li X., Wang Z., Wang L., Pan M., Gao P. Liver cirrhosis: a risk factor for gallstone disease in chronic hepatitis C patients in China. Medicine (Baltimore). 2017;Jun;96(26):e7427. doi: 10.1097/MD.0000000000007427.
6. Slouha E., Biput S.J., Kuteyi A., et al. Non-alcoholic Fatty Liver Disease and Gallstones: A Systematic Review. Cureus. 2023 Sep 11;15(9):e45027. doi: 10.7759/cureus.45027.
7. Sheen I.S., Liaw Y.F. The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. Hepatology. 1989 Apr;9(4):538–40. doi: 10.1002/hep.1840090405.
8. Luo X., Yang W., Joshi A.D., et al. Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts. Br J Cancer. 2022 Oct;127(6):1069–1075. doi: 10.1038/s41416-022-01877-5.
9. Li X., Guo X., Ji H., Yu G., Gao P. Gallstones in Patients with Chronic Liver Diseases. Biomed Res Int. 2017;2017:9749802. doi: 10.1155/2017/9749802.
10. Mathurin P., Vidaud D., Vidaud M., et al. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology. 1996 Jan;23(1):44–51. doi: 10.1002/hep.510230107.
11. LaMont J.T., Ventola A.S., Trotman B.W., Soloway R.D. Mucin glycoprotein content of human pigment gallstones. Hepatology. 1983 May-Jun;3(3):377–82. doi: 10.1002/hep.1840030316.
12. Moore E.W. Biliary calcium and gallstone formation. Hepatology. 1990 Sep;12(3 Pt 2):206S-214S; discussion 214S-218S.
13. Cahalane M.J., Neubrand M.W., Carey M.C. Physical-chemical pathogenesis of pigment gallstones. Semin Liver Dis. 1988 Nov;8(4):317-28. doi: 10.1055/s-2008-1040553.
14. Alvaro D., Angelico M., Gandin C., et al. Physico-chemical factors predisposing to pigment gallstone formation in liver cirrhosis. J Hepatol. 1990 Mar;10(2):228-34. doi: 10.1016/0168-8278(90)90057-x.
15. Whiting J.F., Narciso J.P., Chapman V., et al. Deconjugation of bilirubin-IX alpha glucuronides: a physiologic role of hepatic microsomal beta-glucuronidase. J Biol Chem. 1993 Nov 5;268(31):23197–201.
16. Diehl A.K., Schwesinger W.H., Holleman D.R. Jr, et al. Clinical correlates of gallstone composition: distinguishing pigment from cholesterol stones. Am J Gastroenterol. 1995 Jun;90(6):967–72.
17. Vlahcevic Z.R., Juttijudata P., Bell C.C. Jr, Swell L. Bile acid metabolism in patients with cirrhosis. II. Cholic and chenodeoxycholic acid metabolism. Gastroenterology. 1972 Jun;62(6):1174–81.
18. Vlahcevic Z.R., Yoshida T., Juttijudata P., et al. Bile acid metabolism in cirrhosis. 3. Biliary lipid secretion in patients with cirrhosis and its relevance to gallstone formation. Gastroenterology. 1973 Feb;64(2):298–303.
19. Freudenberg F., Broderick A.L., Yu B.B., et al. Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am J Physiol Gastrointest Liver Physiol. 2008 Jun;294(6):G1411–20. doi: 10.1152/ajpgi.00181.2007.
20. Vitek L., Carey M.C. Enterohepatic cycling of bilirubin as a cause of ‘black’ pigment gallstones in adult life. Eur J Clin Invest. 2003 Sep;33(9):799–810. doi: 10.1046/j.1365-2362.2003.01214.x.
21. Fornari F., Imberti D., Squillante M.M., et al. Incidence of gallstones in a population of patients with cirrhosis. J Hepatol. 1994 Jun;20(6):797-801. doi: 10.1016/s0168-8278(05)80152-7.
22. Benvegnù L., Noventa F., Chemello L., et al. Prevalence and incidence of cholecystolithiasis in cirrhosis and relation to the etiology of liver disease. Digestion. 1997;58(3):293–8. doi: 10.1159/000201457.
23. Conte D., Barisani D., Mandelli C., et al. Cholelithiasis in cirrhosis: analysis of 500 cases. Am J Gastroenterol. 1991 Nov;86(11):1629–32.
24. Goebel K.M., Goebel F.D., Schubotz R., Schneider J. Hemolytic implications of alcoholism in liver disease. J Lab Clin Med. 1979 Jul;94(1):123–32.
25. Schwesinger W.H., Kurtin W.E. Effects of ethanol infusion on serum hemoglobin and bile pigments. J Surg Res. 1984 Jul;37(1):43–7. doi: 10.1016/0022-4804(84)90159-8.
26. Ballantyne B., Wood W.G. Biochemical and histochemical observations on Beta-glucuronidase in the mammalian gallbladder. Am J Dig Dis. 1968 Jun;13(6):551–7. doi: 10.1007/BF02233068.
27. Elzouki A.N., Nilsson S., Nilsson P., et al. The prevalence of gallstones in chronic liver disease is related to degree of liver dysfunction. Hepatogastroenterology. 1999 Sep-Oct;46(29):2946–50.
28. Stroffolini T., Sagnelli E., Mele A., Cottone C., Almasio P.L.; Italian Hospitals’ Collaborating Group. HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. J Viral Hepat. 2007 Sep;14(9):618–23. doi: 10.1111/j.1365-2893.2007.00845.x.
29. Chang T.S., Lo S.K., Shyr H.Y., et al. Hepatitis C virus infection facilitates gallstone formation. J Gastroenterol Hepatol. 2005 Sep;20(9):1416–21. doi: 10.1111/j.1440-1746.2005.03915.x.
30. Acalovschi M., Buzas C., Radu C., Grigorescu M. Hepatitis C virus infection is a risk factor for gallstone disease: a prospective hospital-based study of patients with chronic viral C hepatitis. J Viral Hepat. 2009 Dec;16(12):860–6. doi: 10.1111/j.1365-2893.2009.01141.x.
31. Hu J.H., Chen M.Y., Yeh C.T., et al. Effects of gender and age on prevalence of cholelithiasis in patients with chronic HCV infection: A community-based cross-sectional study in an HCV-hyperendemic area. Medicine (Baltimore). 2018 Jun;97(22):e10846. doi: 10.1097/MD.0000000000010846.
32. Li X., Gao P. Hepatitis C Virus Infection Increases Risk of Gallstone Disease in Elderly Chinese Patients with Chronic Liver Disease. Sci Rep. 2018 Mar 15;8(1):4636. doi: 10.1038/s41598-018-22896-4.
33. Плотникова Е.Ю., Карягина М.С., Шамрай М.А., Баранова Е.Н. Билиарный статус у пациентов с хроническими гепатитами В и С. Лечащий врач. 2017;8:47–53.
34. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17–35. doi: 10.1055/s-2000-9505.
35. Bini E.J., McGready J. Prevalence of gallbladder disease among persons with hepatitis C virus infection in the United States. Hepatology. 2005 May;41(5):1029–36. doi: 10.1002/hep.20647.
36. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323.
37. Fracanzani A.L, Valenti L., Russello M., et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One. 2012;7(7):e41183. doi: 10.1371/journal.pone.0041183.
38. Ahmed M.H., Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol. 2014 May;49(5):521–7. doi: 10.3109/00365521.2014.894119.
39. Lu Y., Hu L., Song J., et al. Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study. BMC Endocr Disord. 2021 Nov 19;21(1):231. doi: 10.1186/s12902-021-00899-z.
40. Lee Y.C., Wu J.S., Yang Y.C., et al. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease. Scand J Gastroenterol. 2014 Aug;49(8):1001–6. doi: 10.3109/00365521.2014.920912.
41. Mallick B., Anand A.C. Gallstone Disease in Cirrhosis-Pathogenesis and Management. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):551–559. doi: 10.1016/j.jceh.2021.09.011.
42. Chang Y., Noh Y.H., Suh B.S., et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018 Nov 21;7(11):458. doi: 10.3390/jcm7110458.
43. Nervi F., Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol. 2013 Jun;108(6):959–61. doi: 10.1038/ajg.2013.84.
44. Biddinger S.B., Haas J.T., Yu B.B., et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008 Jul;14(7):778–82. doi: 10.1038/nm1785.
45. Sun H., Warren J., Yip J., et al. Factors Influencing Gallstone Formation: A Review of the Literature. Biomolecules. 2022 Apr 6;12(4):550. doi: 10.3390/biom12040550.
46. Ryan M.C., Wilson A.M., Slavin J., et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2005 May;28(5):1222–4. doi: 10.2337/diacare.28.5.1222.
47. Koller T., Kollerova J., Hlavaty T., et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012 Feb;47(2):197–203. doi: 10.3109/00365521.2011.643481.
48. Alsaif F.A, Alqahtani S.H., Alsadoon A.M., et al. Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi J Gastroenterol. 2020 Apr 14;26(4):204–9. doi: 10.4103/sjg.SJG_29_20.
49. Jaruvongvanich V., Sanguankeo A., Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016 Aug;61(8):2389–2396. doi: 10.1007/s10620-016-4125-2.
50. Shen S.S., Gong J.J., Wang X.W., et al. Promotional effect of nonalcoholic fatty liver disease on Gallstone disease: A systematic review and meta-analysis. Turk J Gastroenterol. 2017 Jan;28(1):31-39. doi: 10.5152/tjg.2016.0357.
51. Arrese M., Cortes V., Barrera F., Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. Curr Opin Gastroenterol. 2018 Mar;34(2):90–96. doi: 10.1097/MOG.0000000000000416.
52. Su P.Y., Hsu Y.C., Cheng Y.F., et al. Strong association between metabolically-abnormal obesity and gallstone disease in adults under 50 years. BMC Gastroenterol. 2019 Jul 4;19(1):117. doi: 10.1186/s12876-019-1032-y.
53. Gu S., Hu S., Wang S., et al. Bidirectional association between NAFLD and gallstone disease: a systematic review and meta-analysis of observational studies. Expert Rev Gastroenterol Hepatol. 2023 Mar;17(3):283–293. doi: 10.1080/17474124.2023.2175671.
54. Rodriguez-Hernandez N., Lazo-de-la-Vega-Monroy M.L., Ruiz-Noa Y., et al. Predictive Models for Non-Alcoholic Fatty Liver Disease Diagnosis in Mexican Patients with Gallstone Disease: Sex-Specific Insights. Diagnostics (Basel). 2024 Jul 11;14(14):1487. doi: 10.3390/diagnostics14141487.
55. Wang H.H., Liu M., Clegg D.J., et al. New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta. 2009 Nov;1791(11):1037–47. doi: 10.1016/j.bbalip.2009.06.006.
56. Sheibani A., Reihani H., Shoja A., et al. Gallstones increase the risk of nonalcoholic fatty liver: A case-control study. Health Sci Rep. 2024 Nov 5;7(11):e70068. doi: 10.1002/hsr2.70068.
57. Sepehrimanesh M., Niknam R., Ejtehadi F., et al. Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran: A Population-Based Study. Diabetes Metab Syndr Obes. 2020 May 1;13:1449–1458. doi: 10.2147/DMSO.S246949.
58. Zhang J., Chen L., Shen K., et al. Association between metabolically healthy overweight/obesity and gallstones in Chinese adults. Nutr Metab (Lond). 2023 Mar 31;20(1):20. doi: 10.1186/s12986-023-00741-4.
59. Man S., Gao Y., Lv J., et al. Metabolically healthy obesity was significantly associated with increased risk of gallstones. Eur J Endocrinol. 2022 Jan 6;186(2):27–-283. doi: 10.1530/EJE-21-0802.
60. Acalovschi M., Dumitraşcu D.L., Csakany I. Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis – a simultaneous sonographic study. Gut. 1997 Mar;40(3):412-7. doi: 10.1136/gut.40.3.412.
61. Davion T., Capron J.P. La lithiase biliaire au cours de la cirrhose: oui, mais pourquoi?
62. Li C.P., Hwang S.J., Lee F.Y., et al. Evaluation of gallbladder motility in patients with liver cirrhosis: relationship to gallstone formation. Dig Dis Sci. 2000 Jun;45(6):1109–14. doi: 10.1023/a:1005537632665.
63. Kao C.H., Hsieh J.F., Tsai S.C., et al. Evidence of impaired gallbladder function in patients with liver cirrhosis by quantitative radionuclide cholescintigraphy. Am J Gastroenterol. 2000 May;95(5):1301–4. doi: 10.1111/j.1572-0241.2000.02029.x.
64. Loreno M., Travali S., Bucceri A.M., et al. Ultrasonographic study of gallbladder wall thickness and emptying in cirrhotic patients without gallstones. Gastroenterol Res Pract. 2009;2009:683040. doi: 10.1155/2009/683040.
65. Buzaş C., Chira O., Mocan T., Acalovschi M. Comparative study of gallbladder motility in patients with chronic HCV hepatitis and with HCV cirrhosis. Rom J Intern Med. 2011;49(1):37–44.
66. Acalovschi M., Dumitrascu D.L., Nicoara C.D.. Gallbladder contractility in liver cirrhosis: comparative study in patients with and without gallbladder stones. Dig Dis Sci. 2004 Jan;49(1):17–24. doi: 10.1023/b:ddas.0000011596.33237.5c.
67. Pompili M., Rapaccini G.L., Caturelli E., et al. Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis. Dig Dis Sci. 1995 Feb;40(2):428–34. doi: 10.1007/BF02065433.
68. Sakamoto T., Fujimura M., Newman J., et al. Comparison of hepatic elimination of different forms of cholecystokinin in dogs. Bioassay and radioimmunoassay comparisons of cholecystokinin-8-sulfate and -33-sulfate. J Clin Invest. 1985 Jan;75(1):280–5. doi: 10.1172/JCI111686.
69. Barreca T., Franceschini R., Cataldi A., Rolandi E. Plasma somatostatin response to an oral mixed test meal in cirrhotic patients. J Hepatol. 1991 Jan;12(1):40–4. doi: 10.1016/0168-8278(91)90906-r.
70. Lewis F.W., Adair O., Hossack K.F., et al. Plasma glucagon concentration in cirrhosis is related to liver function but not to portal-systemic shunting, systemic vascular resistance, or urinary sodium excretion. J Lab Clin Med. 1991 Jan;117(1):67–75.
71. Attili A.F., De Santis A., Capri R., et al. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology. 1995 Mar;21(3):655–60. doi: 10.1002/hep.1840210309.
72. Maggi A., Solenghi D., Panzeri A., et al. Prevalence and incidence of cholelithiasis in patients with liver cirrhosis. Ital J Gastroenterol Hepatol. 1997 Aug;29(4):330–5.
73. Leopold G.R., Amberg J., Gosink B.B., Mittelstaedt C. Gray scale ultrasonic cholecystography: a comparison with conventional radiographic techniques. Radiology. 1976 Nov;121(2):445–8. doi: 10.1148/121.2.445.
74. Ishizaki Y., Bandai Y, Shimomura K., et al. Management of gallstones in cirrhotic patients. Surg Today. 1993;23(1):36–9. doi: 10.1007/BF00308997.
75. Gibney E.J. Asymptomatic gallstones. Br J Surg. 1990 Apr;77(4):368–72. doi: 10.1002/bjs.1800770405.
76. Castaing D., Houssin D., Lemoine J., Bismuth H. Surgical management of gallstones in cirrhotic patients. Am J Surg. 1983 Sep;146(3):310–3. doi: 10.1016/0002-9610(83)90403-8.
77. Bloch R.S., Allaben R.D., Walt A.J. Cholecystectomy in patients with cirrhosis. A surgical challenge. Arch Surg. 1985 Jun;120(6):669-72. doi: 10.1001/archsurg.1985.01390300019003.
78. Puggioni A., Wong L.L. A metaanalysis of laparoscopic cholecystectomy in patients with cirrhosis. J Am Coll Surg. 2003 Dec;197(6):921–6. doi: 10.1016/j.jamcollsurg.2003.08.011.
79. Yerdel M.A., Tsuge H., Mimura H., et al. Laparoscopic cholecystectomy in cirrhotic patients: expanding indications. Surg Laparosc Endosc. 1993 Jun;3(3):180–3.
80. Fernandes N.F., Schwesinger W.H., Hilsenbeck S.G., et al. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May;6(3):340–4. doi: 10.1053/lv.2000.6353.
81. Yeh C.N., Chen M.F., Jan Y.Y. Laparoscopic cholecystectomy in 226 cirrhotic patients. Experience of a single center in Taiwan. Surg Endosc. 2002 Nov;16(11):1583–7. doi: 10.1007/s00464-002-9026-0.
82. Hanson B., Roat J., Pocha C. Cholecystitis and gallbladder perforation in cirrhotic patients: a clinical dilemma. Dig Liver Dis. 2014 Oct;46(10):960–1. doi: 10.1016/j.dld.2014.05.018.
83. Quillin R.C. 3rd, Burns J.M., Pineda J.A., et al. Laparoscopic cholecystectomy in the cirrhotic patient: predictors of outcome. Surgery. 2013 May;153(5):634–40. doi: 10.1016/j.surg.2012.11.012.
84. Плотникова Е.Ю. Известный и неизвестный гимекромон. Consilium Medicum. 2024; 5(26):324–330. doi: 10.26442/20751753.2024.5.202877.
85. Takeda S., Aburada M. The choleretic mechanism of coumarin compounds and phenolic compounds. J Pharmacobiodyn. 1981 Sep;4(9):724–34. doi: 10.1248/bpb1978.4.724.
86. Hoffmann R.M., Schwarz G., Pohl C., et al. Gallensäure-unabhängige Wirkung von Hymecromon auf die Gallesekretion und die Motilität der Gallenwege
87. Andreichenko I.N., Tsitrina A.A., Fokin A.V., et al. 4-methylumbelliferone Prevents Liver Fibrosis by Affecting Hyaluronan Deposition, FSTL1 Expression and Cell Localization. Int J Mol Sci. 2019 Dec 13;20(24):6301. doi: 10.3390/ijms20246301.
88. Matsuda M., Seki E. The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix. Food Chem Toxicol. 2020 Sep;143:111556. doi: 10.1016/j.fct.2020.111556.
89. Kim S.M., Song G.Y., Shim A., et al. Hyaluronan synthase 2, a target of miR-200c, promotes carbon tetrachloride-induced acute and chronic liver inflammation via regulation of CCL3 and CCL4. Exp Mol Med. 2022 Jun;54(6):739–752. doi: 10.1038/s12276-022-00781-5.
Об авторах / Для корреспонденции
Екатерина Юрьевна Плотникова, д.м.н., профессор, профессор кафедры последипломной подготовки и сестринского дела, руководитель курса клинической гастроэнтерологии, Кемеровский государственный медицинский университет, Кемерово, Россия; eka-pl@rambler.ru, ORCID: https://orcid.org/0000-0002-6150-1808 (автор, ответственный за переписку)Людмила Георгиевна Вологжанина, к.м.н., доцент кафедры факультетской терапии № 1, Пермский государственный медицинский университет им. академика Е.А. Вагнера; директор ООО «Гастроцентр», Пермь, Россия; ludovica@mail.ru, ORCID: https://orcid.org/0000-0003-3105-4645
Артур Закирчанович Азанов, врач-гастроэнтеролог, поликлиническое отделение, Юргинская районная больница, Юрга, Россия;
artur_zakir@mail.ru, ORCID: https://orcid.org/0009-0005-0152-4222
Андрей Сергеевич Сухих, к.м.н., зав. лабораторией «Физико-химических исследований фармакологически активных и природных соединений», Кемеровский государственный медицинский университет, Кемерово, Россия; suhih_as@list.ru, ORCID: https://orcid.org/0000-0001-9300-5334
Также по теме
